The challenge of this project is to improve the performance of our biosensors, to improve their range and effectiveness for detecting different biomarkers, keeping them label-free and providing quantitative information through a simple and low-cost measurement system.
The objectives pursued by this project are two. First, validate the potential of the consortium’s proprietary antibodies in early diagnosis in Alzheimer’s patients. Second, obtain a first proof of concept that confirms the viability and efficacy of an immunotherapy based on those antibodies.
In this project we are going to develop a new assay methodology for the early detection of AIDS through the detection of the p24 protein in blood, which appears a few days after the patient has been infected. Using our technology, we will improve the limit of detection in the recognition of target molecules.
BiOD is the lead partner for the read-out hardware and fully responsible for coordinating the commercial exploitation of the AllerScreening platform.
This project intends to carry out a proof of concept of biod technology for its application to the detection of biomarkers related to Alzheimer’s disease (TAU and beta-amyloid protein).
In this project we will experimentally test and validate a PoC device based on our technology for the simultaneous measurement of three biomarkers (proteins MMP9, S100A6 and CST4) associated with the ophthalmological pathology of dry eye.
BiOD is participating in the design and integration of the different modules within the Chemical Detection Unit (CDU) up to the feasibility study for the final user. It includes the installation of the first CDU prototype and fabrication of the chip exchanging mechanism.
The role of BiOD in this project is the optimization of the readout platform for its application in the field of allergy detection, equipping it with the necessary multiplexing capability through an automation system.
The main objective of the INNBIOD project is to develop an innovative PoC system based on disposable diagnostic KITs based on biochips and portable reading platforms, low cost and oriented to the end user